Oxford, UK - 6 October 2006: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that it has presented further encouraging data from six Phase II trials of TroVax, its lead cancer immunotherapy product, at the 14th International Cancer Immunotherapy Meeting, which is sponsored by the Cancer Research Institute and the Academy of Cancer Immunology and is being held from 4-6 October 2006, in New York City.
